| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 03/21/2002 | WO2002022111A2 Combination of lipoic acids and conjugated acids for treating diabetic disorders |
| 03/21/2002 | WO2002022088A1 Hair nourishments and method of screening the same |
| 03/21/2002 | WO2001087039A3 Treatment of neoplasia / transformation using pituitary tumor transforming gene 2 |
| 03/21/2002 | WO2001081346A3 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 03/21/2002 | WO2001078529A3 Compositions and methods for improving vascular health |
| 03/21/2002 | WO2001077376A8 Diagnosis of diseases associated with metastasis |
| 03/21/2002 | WO2001077164A8 Diagnosis of diseases associated with apoptosis by means of assessing the methylation status of genes associated with apoptosis |
| 03/21/2002 | WO2001070694A8 Amorphous torasemide modification |
| 03/21/2002 | WO2001068859A3 Il-17 receptor like molecules and uses thereof |
| 03/21/2002 | WO2001068568A3 Il-8 receptor antagonists |
| 03/21/2002 | WO2001066099A3 Use of quinazoline derivatives as angiogenesis inhibitors |
| 03/21/2002 | WO2001064837A3 β NETRIN AND USES THEREOF |
| 03/21/2002 | WO2001064165A3 Il-8 receptor antagonists |
| 03/21/2002 | WO2001051638A3 Drug metabolizing enzymes |
| 03/21/2002 | US20020035737 Cloning pigs using donor nuclei from differentiated cells |
| 03/21/2002 | US20020035151 Calcium formate for use as a dietary supplement |
| 03/21/2002 | US20020035147 Nervous system, psychological disorders |
| 03/21/2002 | US20020035140 1-(pyrrlolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 03/21/2002 | US20020035139 COX-2 inhibitors and the prevention of the side effects of radiation therapy |
| 03/21/2002 | US20020035110 Treatment or prevention of disorders of the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, and sleep apnea |
| 03/21/2002 | US20020034515 Proteus mirabilis-based vaccine |
| 03/21/2002 | DE10045059A1 Therapeutische Kombination von Liponsäure und Konjuensäuren zur Behandlung diabetischer Störungen The therapeutic combination of lipoic acid and conjugated fatty acids for the treatment of diabetic disorders |
| 03/21/2002 | DE10044325A1 Neue MMP-2-Derivate als Inhibitoren des Integrins avbeta3 New MMP-2 derivatives as inhibitors of the integrin avbeta3 |
| 03/21/2002 | CA2422586A1 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
| 03/21/2002 | CA2422376A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | CA2422137A1 Tetrahydroquinoline compounds |
| 03/21/2002 | CA2422076A1 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | CA2422055A1 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| 03/21/2002 | CA2421966A1 Remedies for ischemic diseases |
| 03/21/2002 | CA2421279A1 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2420450A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2419219A1 Chemokine receptor binding heterocyclic compounds |
| 03/21/2002 | CA2418720A1 Caspase inhibitors and uses thereof |
| 03/20/2002 | EP1188440A1 Medicinal composition for oral administration |
| 03/20/2002 | EP1187931A1 49 human secreted proteins |
| 03/20/2002 | EP1187843A1 Angiogenic proteins and uses thereof |
| 03/20/2002 | EP1187836A1 Substituted imidazothiazoles as antidepressant agents |
| 03/20/2002 | EP1187627A2 Uses of h-trek-1 polypeptides and polynucleotides encoding them |
| 03/20/2002 | EP1187539A1 Method and composition for masking mineral taste |
| 03/20/2002 | EP1187531A1 Macrophage scavenger receptor antagonists |
| 03/20/2002 | EP0642351B1 New pharmaceutical uses of krill enzymes |
| 03/20/2002 | CN1341099A 2-aminopyridines containing fused ring substituents |
| 03/19/2002 | US6359181 Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents |
| 03/19/2002 | US6359130 Bridged indenopyrrolocarbazoles |
| 03/19/2002 | US6358985 Inhibitors of prenyl-protein transferase |
| 03/19/2002 | US6358983 Heterocyclically substituted α-hydroxycarboxylic acid derivatives, method for producing the same and their use as endothelin receptor antagonists |
| 03/19/2002 | US6358956 Inhibitors of prenyl-protein transferase |
| 03/19/2002 | US6358954 PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| 03/19/2002 | US6358945 Compounds useful as anti-inflammatory agents |
| 03/19/2002 | US6358741 Polynucleotide coding propagation regulator; for treating cell proliferative defects |
| 03/19/2002 | US6358706 Nucleotide sequences coding membrane protein; for use in treatment of epilepsy, schizophrenia, depression, sleep, stress, muscle, endocrine, respiratory, fertility, contraceptive, cardiovascular disorders and atherosclerosis |
| 03/19/2002 | CA2251453C 5-arylalkyl-substituted pyrazolo(4,3-d)pyrimidine-7-ones |
| 03/19/2002 | CA2236673C (-)cis-6(s)-phenyl-5(r)-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol d-tartrate |
| 03/14/2002 | WO2002021141A2 Methods and compositions for diseases associated with amyloidosis |
| 03/14/2002 | WO2002020822A2 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 03/14/2002 | WO2002020769A1 Human and mouse targeting peptides identified by phage display |
| 03/14/2002 | WO2002020736A2 Proteases |
| 03/14/2002 | WO2002020724A2 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 03/14/2002 | WO2002020723A2 Compositions and methods for targeting peptides in humans in vivo |
| 03/14/2002 | WO2002020722A2 Methods and compositions for in vitro targeting |
| 03/14/2002 | WO2002020619A2 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| 03/14/2002 | WO2002020615A2 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders |
| 03/14/2002 | WO2002020553A1 NOVEL POLYMORPHIC FORM OF 17-β-(N-TER.BUTYL CARBAMOYL)-4-AZA-5-α-ANDROST-1-EN-3-ONE AND A PROCESS FOR PREPARING IT |
| 03/14/2002 | WO2002020533A2 Benzoxazine alpha-1 adrenergic compounds |
| 03/14/2002 | WO2002020519A1 The hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
| 03/14/2002 | WO2002020489A2 QUINOLINE INHIBITORS OF cGMP PHOSPHODIESTERASE |
| 03/14/2002 | WO2002020488A2 Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor |
| 03/14/2002 | WO2001070757A3 Thioketals and thioethers for inhibiting the expression of vcam-1 |
| 03/14/2002 | WO2001064671A3 Haloimidazole derivatives and their use as muscarinic m3 and serotoninergic 5-ht4 receptors |
| 03/14/2002 | WO2001064668A3 1,3-dihydro-2h-indol-2-one, and their use as v1b or both v1b and v1a arginine-vasopressin ligand receptors |
| 03/14/2002 | WO2001058852A3 (r)-2-aryl-propionamides, useful in the inhibition of il-8-induced chemiotaxis of neutrophils |
| 03/14/2002 | WO2001055134A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vassopressin receptors |
| 03/14/2002 | WO2001055130A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors |
| 03/14/2002 | WO2001036684A3 Mammalian toxicological response markers |
| 03/14/2002 | US20020032332 Hypotensive agents, antiallergens, antiasthma, treating bronchospasm, dysmenorrhea, esophageal spasm, glaucoma, premature labor, urinary tract disorder, gastrointestinal motility or cardiovascular disorders |
| 03/14/2002 | US20020032225 Treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis. |
| 03/14/2002 | US20020032224 Treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system disorders |
| 03/14/2002 | US20020032219 Use of alpha-1c specific compounds to treat benign prostatic hyperplasia |
| 03/14/2002 | US20020032212 A tricyclic compound (with oxy and nitrogen atoms in the ring); perticularly useful for treating or preventing psoriasis and other skin diseases |
| 03/14/2002 | US20020032204 Reacting a substituted indol-2-one compound with an acyclic or cyclic amine free of piperidine-1-yl or morpholine-4-yl to form protein kinase inhibitor |
| 03/14/2002 | US20020032191 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors |
| 03/14/2002 | US20020032157 Methods of inhibiting ectopic calcification |
| 03/14/2002 | US20020031531 Immunotherapy for lung or urogenital cancer |
| 03/14/2002 | DE10043667A1 2-Guanidino-4-aryl-chinazoline 2-guanidino-4-aryl-quinazolines |
| 03/14/2002 | DE10042997A1 Thienopyrimidine Thienopyrimidines |
| 03/14/2002 | DE10023486C1 Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel Ortho-substituted anthranilic acid amides and their use as medicaments |
| 03/14/2002 | CA2422204A1 Human antibodies against pseudomonas aeruginosa lps derived from transgenic mice |
| 03/14/2002 | CA2422159A1 Novel polymorphic form of 17-beta-(n-ter.butyl carbamoyl)-4-aza-5-alpha-androst-1-en-3-one and a process for preparing it |
| 03/14/2002 | CA2421922A1 Proteases |
| 03/14/2002 | CA2421842A1 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders |
| 03/14/2002 | CA2421380A1 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 03/14/2002 | CA2421374A1 Methods and compositions for diseases associated with amyloidosis |
| 03/14/2002 | CA2421271A1 Human and mouse targeting peptides identified by phage display |
| 03/14/2002 | CA2421213A1 The hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
| 03/14/2002 | CA2421200A1 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 03/14/2002 | CA2421195A1 Compositions and methods for targeting peptides in humans in vivo |
| 03/14/2002 | CA2421191A1 Methods and compositions for in vitro targeting |
| 03/14/2002 | CA2420703A1 Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor |
| 03/13/2002 | EP1185700A1 49 human secreted proteins |
| 03/13/2002 | EP1185637A1 ANTISENSE TO i c-myc /i FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE |